Evusheld®(tixagevimab+ cilgavimab; AZD7442) was the first anti-Spike monoclonal
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …

The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …

The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …

Abstract In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified,
and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron
subvariants, including BQ. 1, BQ. 1.1, BA. 4.6, BF. 7, and BA. 2.75. 2. Here, we examine the …

The newly emerged SARS-CoV-2 saltation variant, BA. 2.86, has raised global concern
(appendix 1 p 7). By Sept 8, 2023, 95 sequences were detected, of which their early …

Background The emergence of immune-escape variants of severe acute respiratory
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide …

SARS-CoV-2 variants acquire mutations in the spike protein that promote immune evasion
and affect other properties that contribute to viral fitness, such as ACE2 receptor binding and …